Congestive heart failure-related anemia and a role for erythropoietin

International Journal of Cardiology

Volumn 117, Issue 3, 2007, Pages 296-305

  Akram, Kamran ^a   Pearlman, Brian L ^a,b,c  

^a ATLANTA MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Anemia; Congestive heart failure; Darbepoietin; Erythropoietin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERROUS GLUCONATE; FOLIC ACID; FUROSEMIDE; IRON; NEUROHORMONE; NITRIC ACID DERIVATIVE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SPIRONOLACTONE;

ANEMIA; CARDIORENAL ANEMIA SYNDROME; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; FEASIBILITY STUDY; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANEMIA; ERYTHROPOIETIN; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 34047119032     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.05.071     Document Type: Review

References (97)

1. Braunwald E. Heart Disease (2001), W.B. Saunders Company, Philadelphia 635
2. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
3. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345 (2001) 1667-1675
4. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
5. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334 (1996) 1349-1355
6. Mehra M.R., Uber P.A., and Francis G.S. Heart failure therapy at a crossroad: are there limits to the neurohormonal model?. J Am Coll Cardiol 41 (2003) 1606-1610
7. McCullough P.A., and Lepor N.E. The deadly triangle of anemia, renal insufficiency, and cardiovascular disease: implications for prognosis and treatment. Rev Cardiovasc Med 6 (2005) 1-10
8. Silverberg D.S., Wexler D., and Iaina A. The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?. J Nephrol 17 (2004) 749-761
9. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110 (2004) 149-154
10. Sabatine M.S., Morrow D.A., Giugliano R.P., et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111 (2005) 2042-2049
11. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., and Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39 (2002) 1780-1786
12. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes. Circulation 107 (2003) 223-225
13. Herzog C.A., Muster H.A., Li S., and Collins A.J. Impact of congestive heart failure, chronic kidney disease, and anemia on survival in the Medicare population. J Card Fail 10 (2004) 467-472
14. Kitzman D.W., Gardin J.M., Gottdiener J.S., et al. Importance of heart failure with preserved systolic function in patients > or = 65 years of age. Cardiovascular Health Study. Am J Cardiol 87 (2001) 413-419
15. O'Meara E., Clayton T., McEntegart M.B., et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 113 (2006) 986-994
16. Felker G.M., Shaw L.K., Stough W.G., and O'Connor C.M. Anemia in patients with heart failure and preserved systolic function. Am Heart J 151 (2006) 457-462
17. Fink J., Blahut S., Reddy M., and Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37 (2001) 348-355
18. Tang W.H., Miller H., Partin M., Harris C.M., and Young J.B. Anemia in ambulatory patients with chronic heart failure: a single-center clinical experience derived from electronic medical records. J Am Coll Cardiol 41 (2003) S1061-S1075 [suppl A]
19. Silverberg D.S., Wexler D., and Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4 (2002) 681-686
20. Das S.R., Dries D.L., Drazner M.H., Yancy C.W., and Chae C.U. Relation of lower Hct to progression from asymptomatic left ventricular dysfunction to symptomatic heart failure. Am J Cardiol 96 (2005) 827-831
21. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
22. Levin A., Djurdjev O., Barrett B., et al. Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 38 (2001) 1398-1407
23. Luthi J.C., Flanders W.D., Burnier M., Burnand B., and McClellan W.M. Anemia and chronic kidney disease are associated with poor outcomes in heart failure patients. BMC Nephrol 7 (2006) 3
24. Harnett J.D., Foley R.N., Kent G.M., Barre P.E., Murray D., and Parfrey P.S. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 47 (1995) 884-890
25. Levin A., Singer J., Thompson C.R., Ross H., and Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 27 (1996) 347-354
26. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
27. McMahon L.P., Mason K., Skinner S.L., Burge C.M., Grigg L.E., and Becker G.J. Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15 (2000) 1425-1430
28. Laskar S.R., and Dries D.L. The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Curr Cardiol Rep 5 (2003) 205-210
29. Fine L.G., Bandyopadhay D., and Norman J.T. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Inter Suppl 75 (2000) S22-S26
30. Yoshida H., Yashiro M., Liang P., et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int 53 (1998) 880-891
31. Schuster S.J., Koury S.T., Bohrer M., Salceda S., and Caro J. Cellular sites of extrarenal and renal erythropoietin production in anemic rats. Br J Haematol 81 (1992) 153-159
32. Vaziri N.D. Erythropoietin and transferrin metabolism in nephrotic syndrome. Am J Kidney Dis 38 (2001) 1-8
33. Iversen P.O., Woldbaek P.R., Tonnessen T., and Christensen G. Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282 (2002) R166-R172
34. Means Jr. R.T. Advances in the anemia of chronic disease. Int J Hematol 70 (1999) 7-12
35. Rossi E. Hepcidin-the iron regulatory hormone. Clin Biochem Rev 26 (2005) 47-49
36. Bolger A.P., Doehner W., Sharma R., Coats J.S., and Anker S. Anemia in chronic heart failure: the relationship to inflammatory cytokine production and prognostic importance. Circulation 106 (2002) S2819 [suppl]
37. Androne A.S., Katz S.D., Lund L., et al. Hemodilution is common in patients with advanced heart failure. Circulation 107 (2003) 226-229
38. Krack A., Sharma R., Figulla H.R., and Anker S.D. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 26 (2005) 2368-2374
39. Macdougall I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14 (1999) 1836-1841
40. Cole J., Ertoy D., Lin H., et al. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J Clin Invest 106 (2000) 1391-1398
41. Gossmann J., Burkhardt R., Harder S., et al. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 60 (2001) 83-86
42. Freudenthaler S.M., Lucht I., Schenk T., Brink M., and Gleiter C.H. Dose-dependent effect of angiotensin II on human erythropoietin production. Pflugers Arch 439 (2000) 838-844
43. Yanase T., Maki T., Nawata H., Kato K., and Ibayashi H. Effect of angiotensin II on secretion of adrenal androgens. Endocrinol Jpn 31 (1984) 741-747
44. Brox A.G., Mangel J., Hanley J.A., St Louis G., Mongrain S., and Gagnon R.F. Erythrocytosis after renal transplantation represents an abnormality of insulin-like growth factor-I and its binding proteins. Transplantation 66 (1998) 1053-1058
45. Azizi M., Rousseau A., Ezan E., et al. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest 97 (1996) 839-844
46. Marathias K.P., Agroyannis B., Mavromoustakos T., Matsoukas J., and Vlahakos D.V. Hct-lowering effect following inactivation of renin-angiotensin system with angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Curr Top Med Chem 4 (2004) 483-486
47. Ishani A., Weinhandl E., Zhao Z., et al. Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45 (2005) 391-399
48. Yildiz A., Cine N., Akkaya V., et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 72 (2001) 542-544
49. Plata R., Cornejo A., Arratia C., et al. Angiotensin-converting-enzyme inhibition therapy in altitude polycythemia: a prospective randomized trial. Lancet 359 (2002) 663-666
50. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
51. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
52. Silverberg D.S., Wexler D., and Blum M. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18 (2003) 141-146
53. Mancini D.M., Katz S.D., Lang C.C., LaManca J., Hudaihed A., and Androne A.S. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107 (2003) 294-299
54. Silverberg D.S., Wexler D., Blum M., et al. Effects of treatment with epoetin Beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 28 (2005) 41-47
55. Mishra T.K., Mishra S.K., Mohanty N.K., and Rath P.K. Prevalence, prognostic importance and therapeutic implications of anemia in heart failure. Indian Heart J 57 (2005) 670-674
56. Egrie J.C., Dwyer E., Browne J.K., et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31 (2003) 290-299
57. Cleland J.G., Sullivan J.T., Ball S., et al. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. J Cardiovasc Pharmacol 46 (2005) 155-161
58. Cleland J.G., Coletta A.P., Clark A.L., Velavan P., and Ingle L. Clinical trials update from the European Society of Cardiology Heart Failure meeting and the American College of Cardiology: darbepoetin alfa study, ECHOS, and ASCOT-BPLA. Eur J Heart Fail 7 (2005) 937-939
59. van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimen of darbepoetin alfa on hemoglobin response and symptoms in patients with heart failure and anemia. J Am Coll Cardiol 47 (2006) 61A [suppl A]
60. NKF-K/DOQI. Clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 37 Suppl 1 (2001) S182-S238
61. Besarab A., Bolton W.K., Browne J.K., et al. The effects of normal as compared with low Hct values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
62. Offner P.J. Age of blood: does it make a difference?. Crit Care (2004) S24-S26 [Suppl 2]
63. Bordin J.O., Heddle N.M., and Blajchman M.A. Biologic effects of leukocytes present in transfused cellular blood products. Blood 84 (1994) 1703-1721
64. Kahn R.C., Zaroulis C., Goetz W., and Howland W.S. Hemodynamic oxygen transport and 2,3-diphosphoglycerate changes after transfusion of patients in acute respiratory failure. Intensive Care Med 12 (1986) 22-25
65. Parsa C.J., Matsumoto A., Kim J., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
66. Grimm C., Wenzel A., Groszer M., et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 8 (2002) 718-724
67. van der Meer P., Lipsic E., Boer R.A., et al. A functional erythropoietin receptor in a rat heart is linked to anti-apoptotic effects. J Am Coll Cardiol 41 (2003) 330A
68. Siren A.L., Fratelli M., Brines M., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci U S A 98 (2001) 4044-4049
69. Anagnostou A., Liu Z., Steiner M., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91 (1994) 3974-3978
70. Namiuchi S., Kagaya Y., Ohta J., et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 45 (2005) 1406-1412
71. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
72. Heeschen C., Aicher A., Lehmann R., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
73. Jaquet K., Krause K., Tawakol-Khodai M., Geidel S., and Kuck K.H. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 64 (2002) 326-333
74. van der Meer P., Lipsic E., Henning R.H., et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 46 (2005) 125-133
75. Liu X., Xie W., Liu P., et al. Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78 (2006) 2255-2264
76. Liu J., Narasimhan P., Song Y.S., et al. Epo protects SOD2-deficient mouse astrocytes from damage by oxidative stress. Glia 53 (2006) 360-365
77. Beguin Y., Loo M., R'Zik S., et al. Early prediction of response to recombinant human erythropoietin in patients with the anemia of renal failure by serum transferrin receptor and fibrinogen. Blood 82 (1993) 2010-2016
78. Littlewood T.J., Zagari M., Pallister C., and Perkins A. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist 8 (2003) 99-107
79. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 16 Suppl 7 (2001) 25-28
80. Uehlinger D.E., Gotch F.A., and Sheiner L.B. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51 (1992) 76-89
81. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., and Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood 84 (1994) 1056-1063
82. Beguin Y. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer. Med Oncol 15 Suppl 1 (1998) S38-S46
83. LibraPharm. Pre-treatment erythropoietin levels cannot be used to predict individual response to epoetin alfa in anaemic cancer patients. Curr Med Res Opin 21 Suppl 2 (2005) S19-S21
84. Albitar S., Genin R., Fen-Chong M., Serveaux M.O., and Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 13 (1998) 1206-1210
85. Erturk S., Nergizoglu G., Ates K., et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hyper-trophy in haemodialysis patients. Nephrol Dial Transplant 14 (1999) 1912-1916
86. Horl W.H., Jacobs C., Macdougall I.C., et al. European best practice guidelines 14-16: inadequate response to epoetin. Nephrol Dial Transplant 15 suppl 4 (2000) S43-S50
87. Hayashi K., Hasegawa K., and Kobayashi S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. Kidney Int 60 (2001) 1910-1916
88. Chew C.G., Weise M.D., and Disney A.P. The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 14 (1999) 2047-2049
89. Schiffl H., and Lang S.M. Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease. Nephron 81 (1999) 106-108
90. Saudan P., Halabi G., Perneger T., Wasserfallen J.B., Wauters J.P., and Martin P.Y. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. J Nephrol 19 (2006) 91-96
91. Punnonen K., Irjala K., and Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 89 (1997) 1052-1057
92. Teehan G.S., Bahdouch D., Ruthazer R., Balakrishnan V.S., Snydman D.R., and Jaber B.L. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis 38 (2004) 1090-1094
93. Weinberg E.D. Iron loading and disease surveillance. Emerg Infect Dis 5 (1999) 346-352
94. Kletzmayr J., Sunder-Plassmann G., and Horl W.H. High dose intravenous iron: a note of caution. Nephrol Dial Transplant 17 (2002) 962-965
95. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
96. Silverberg D.S., Blum M., Peer G., Kaplan E., and Iaina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 72 (1996) 413-417
97. Auerbach M., Ballard H., Trout J.R., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307